Can Biogen’s revolutionary new Alzheimer’s treatments save the company’s valuation, or is the massive market sell-off a warning sign for investors?
What does the Biogen LEQEMBI Approval mean for patients?
The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once-weekly formulation of LEQEMBI IQLIK (lecanemab-irmb). This subcutaneous injection is approved as an initiation dose for patients suffering from early-stage Alzheimer’s disease, specifically those with mild cognitive impairment or mild dementia. Developed in collaboration with Eisai Co., Ltd., the new injection method offers a highly anticipated alternative to traditional intravenous infusions.
A major catalyst behind the Biogen LEQEMBI Approval is the convenience of at-home administration. According to an autoinjector acceptability study, 94% of patients and their caregivers found the subcutaneous device easy to use, expressing high levels of satisfaction. The U.S. launch of the weekly initiation dose is scheduled for late August 2026. Clinical data from the Phase 3 Clarity AD long-term extension study confirmed that the subcutaneous delivery achieves therapeutic exposure equivalent to intravenous dosing, maintaining similar efficacy in amyloid removal while showing a comparable safety profile regarding brain swelling adverse events.
How did diranersen perform in Phase 2 clinical trials?
Simultaneously, Biogen Inc. presented highly anticipated Phase 2 CELIA trial data for diranersen at the Alzheimer’s Association International Conference (AAIC). Diranersen, an antisense oligonucleotide licensed from Ionis Pharmaceuticals, targets tau—a protein that forms destructive tangles in the brains of Alzheimer’s patients. Unlike current treatments that focus primarily on amyloid plaque removal, diranersen is designed to stop the production of tau and actively clear existing tangles.
The Phase 2 results demonstrated a robust 50% to 65% reduction in cerebrospinal fluid total tau and a significant reduction in brain tau pathology. The 60 mg dose, administered intrathecally every six months, showed the strongest clinical response at 18 months, slowing cognitive decline by 26% on the Clinical Dementia Rating Sum of Boxes (CDR-SB) scale. This performance closely rivals the 27% cognitive slowing achieved by the approved intravenous formulation of LEQEMBI, prompting the company to advance diranersen into confirmatory Phase 3 development.
Why did the stock decline despite the positive news?
Despite the dual breakthroughs of the Biogen LEQEMBI Approval and the promising diranersen data, the stock experienced a sharp intraday sell-off. Shares of the company fell over 8% to trade around $192.28 on Tuesday, making it one of the weakest performers in the S&P 500 during the session. This decline snapped a two-day winning streak and put the stock on pace for its largest single-day percentage drop in years.
The magnitude of tau reduction and cognitive benefit observed in Celia is among the most compelling reported to date in Alzheimer’s disease drug development.— Cath Mummery, Professor of Clinical Neurology at UCL
Market analysts suggest the sell-off is a classic “sell the news” reaction, compounded by the fact that higher doses of diranersen in the CELIA trial did not correlate with a greater slowing of cognitive decline. Additionally, competitive pressures from rival treatments, such as Eli Lilly’s Kisunla—which previously demonstrated a 35% slower decline on the CDR-SB scale—kept investors cautious. However, the unique administration of diranersen as a twice-yearly lumbar puncture without the brain-swelling side effects typical of amyloid-targeting drugs remains a highly competitive advantage.
